DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cabergoline (Cabergoline) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Cabergoline tablets, USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.

DOSAGE AND ADMINISTRATION

The recommended dosage of cabergoline tablets for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient’s serum prolactin level. Before initiating treatment, cardiovascular evaluation should be performed and echocardiography should be considered to assess for valvular disease.

Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient’s response to each dosage level. If the patient does not respond adequately, and no additional benefit is observed with higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered. Patients receiving long term treatment with cabergoline should undergo periodic assessment of their cardiac status and echocardiography should be considered.

After a normal serum prolactin level has been maintained for 6 months, cabergoline may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when treatment with cabergoline should be reinstituted. The durability of efficacy beyond 24 months of therapy with cabergoline has not been established.

HOW SUPPLIED

Cabergoline tablets, USP 0.5 mg are white to off-white, capsule shaped, flat-faced, bevel-edged tablets with ‘C’ breakline ‘5’ on one side and '>' partial bisect '>' on the other side.

Cabergoline tablets, USP 0.5 mg are available as follows:

Bottles of 8 tablets      NDC 16252-536-08

STORAGE

Store at Controlled Room Temperature 20° to 25°C (68° to 77°F); Excursions permitted to 15° to 30°C (59° to 86°F) [See USP].

Manufactured by:
Cobalt Pharmaceuticals Inc.
Mississauga, Ontario, Canada, L5N 2B8

Distributed by:
Watson Pharma, Inc.
Parsippany, NJ 07054 USA

Revised: October 2012
103-773-02

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017